INGREZZA SPRINKLE (valbenazine tosylate)
INGREZZA SPRINKLE is indicated for the treatment of Tardive Dyskinesia; Chorea; Huntington's Disease.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2024-04-30
- Patent Cliff
- 2040
- Routes
- ORAL
- Dosage Forms
- CAPSULE
INGREZZA SPRINKLE Approval History
What INGREZZA SPRINKLE Treats
3 indicationsINGREZZA SPRINKLE is approved for 3 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Tardive Dyskinesia
- Chorea
- Huntington's Disease
INGREZZA SPRINKLE Target & Pathway
ProTarget
INGREZZA SPRINKLE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to INGREZZA SPRINKLE
3 of 5FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
INGREZZA SPRINKLE FDA Label Details
Indications & Usage
FDA Label (PDF)INGREZZA SPRINKLE is indicated for the treatment of Tardive Dyskinesia; Chorea; Huntington's Disease.
INGREZZA SPRINKLE Patents & Exclusivity
Patents (22 active)
Exclusivity
Pro Intelligence Preview
Deep insights for INGREZZA SPRINKLE
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2040
- • 297 active patents
Trial Analysis
- • 18 total trials
- • Stage: Stable
Competitive Landscape
- • 5 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment